Integral Health Asset Management’s Heron Therapeutics HRTX Stock Holding History

Integral Health Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-700,000	Closed	-$2.95M	–	77
2022 Q3	$2.95M	Sell	700,000 -300,000	-30%	-$1.17M	0.57%	56
2022 Q2	$2.79M	Hold	1,000,000	–	–	0.57%	52
2022 Q1	$5.72M	Buy	1,000,000 +250,000	+33%	+$1.83M	1.49%	27
2021 Q4	$6.85M	Buy	750,000 +340,000	+83%	+$3.47M	1.89%	20
2021 Q3	$4.38M	Buy	410,000 +310,000	+310%	+$3.77M	1.26%	31
2021 Q2	$1.55M	Buy	+100,000	New	+$1.59M	0.43%	59

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Integral Health Asset Management's HRTX Position: Q4 2022 in Review

Integral Health Asset Management sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 700,000 shares — an estimated $2.95M sold.

Integral Health Asset Management first reported a position in HRTX in Q2 2021 and held it in 6 quarters. The position peaked at $6.85M in Q4 2021. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

Integral Health Asset Management reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
Integral Health Asset Management sold 700,000 Heron Therapeutics shares in Q4 2022, an estimated $2.95M.
Integral Health Asset Management first reported a position in Heron Therapeutics in Q2 2021 and held it in 6 quarters.
Integral Health Asset Management's Heron Therapeutics position peaked at $6.85M in Q4 2021.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Integral Health Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.